This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
P21 (P021)
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict WATCH-LIST LOW
"Robust preclinical (rodent AD/TBI/aging) data on neurogenesis + cognitive rescue, plus mechanistic appeal to this user's brain-priority thesis (BDNF axis, anti-amyloid, hippocampal). However: human evidence is essentially absent (Phase 1 safety only), gray-market sourcing is variable, and Cerebrolysin already covers the same neurotrophic-mimetic space with decades of human RCT data. Would upgrade to OPTIONAL-ADD if (a) Phase 2 human data reads out positive, (b) reliable QC'd vendor channel emerges, (c) this user accumulates subjective signal that Cerebrolysin alone leaves gaps in."
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
★20–30, brain-priority, high cognitive workload (this-archetype) | WATCH-LIST | low. Mechanism appealing for MMA brain protection (BDNF axis, neurogenesis, anti-amyloid all map to subconcussive prophylaxis thesis), but Cerebrolysin already covers this space with vastly better human evidence and reliable sourcing. Adding P21 is mechanism-redundant. Revisit if (a) Phase 2 human data positive, (b) Cerebrolysin proves insufficient subjectively, (c) a user in this archetype wants experimental layer beyond core stack. |
30–50, executive maintenance | SKIP-FOR-NOW | Healthy-adult cognitive enhancement evidence is anecdotal-only. Cerebrolysin or NASA delivers same axis with better support. |
50+, mild cognitive decline | WATCH-LIST | experimental. This is the closest match to P21's preclinical evidence base (3xTg-AD model). If Phanes Biotech reads out positive Phase 2 in MCI/early AD, this category becomes "STRONG-CANDIDATE pending availability." Currently: enroll in trials if eligible, don't gray-market. |
Anxiety-prone | SKIP | Wrong tool. Selank, theanine, behavioral interventions higher-yield. |
High athletic load, tested status (WADA-relevant) | WATCH-LIST | Not on WADA Prohibited List as of 2026. CNTF analogs not currently classified, but the WADA monoclonal antibody / growth-factor mimetic categories are evolving — verify before competition. Theoretical brain-protection appeal for combat sports, but evidence too thin to recommend over Cerebrolysin. |
Sleep-disordered | SKIP | Not a sleep tool. |
Recovery-focused (post-injury, post-illness, post-surgery) | WATCH-LIST | TBI rodent data is the closest mechanistic match. If the user ever takes a real concussion, Cerebrolysin (CAPTAIN protocol) is the playbook — P21 is at best an experimental add-on, never a substitute. |
Strength/anabolic-focused | SKIP | Wrong category entirely. |
Older neurodegeneration (Alzheimer's, vascular dementia, MCI) | WATCH-LIST | experimental. Most defensible use case mechanistically (preclinical AD-rescue data is the strongest part of the P21 evidence package), but only via clinical trial enrollment. Gray-market self-administration in this population carries higher risk. |
- ★20–30, brain-priority, high cognitive workload (this-archetype)WATCH-LIST
low. Mechanism appealing for MMA brain protection (BDNF axis, neurogenesis, anti-amyloid all map to subconcussive prophylaxis thesis), but Cerebrolysin already covers this space with vastly better human evidence and reliable sourcing. Adding P21 is mechanism-redundant. Revisit if (a) Phase 2 human data positive, (b) Cerebrolysin proves insufficient subjectively, (c) a user in this archetype wants experimental layer beyond core stack.
- 30–50, executive maintenanceSKIP-FOR-NOW
Healthy-adult cognitive enhancement evidence is anecdotal-only. Cerebrolysin or NASA delivers same axis with better support.
- 50+, mild cognitive declineWATCH-LIST
experimental. This is the closest match to P21's preclinical evidence base (3xTg-AD model). If Phanes Biotech reads out positive Phase 2 in MCI/early AD, this category becomes "STRONG-CANDIDATE pending availability." Currently: enroll in trials if eligible, don't gray-market.
- Anxiety-proneSKIP
Wrong tool. Selank, theanine, behavioral interventions higher-yield.
- High athletic load, tested status (WADA-relevant)WATCH-LIST
Not on WADA Prohibited List as of 2026. CNTF analogs not currently classified, but the WADA monoclonal antibody / growth-factor mimetic categories are evolving — verify before competition. Theoretical brain-protection appeal for combat sports, but evidence too thin to recommend over Cerebrolysin.
- Sleep-disorderedSKIP
Not a sleep tool.
- Recovery-focused (post-injury, post-illness, post-surgery)WATCH-LIST
TBI rodent data is the closest mechanistic match. If the user ever takes a real concussion, Cerebrolysin (CAPTAIN protocol) is the playbook — P21 is at best an experimental add-on, never a substitute.
- Strength/anabolic-focusedSKIP
Wrong category entirely.
- Older neurodegeneration (Alzheimer's, vascular dementia, MCI)WATCH-LIST
experimental. Most defensible use case mechanistically (preclinical AD-rescue data is the strongest part of the P21 evidence package), but only via clinical trial enrollment. Gray-market self-administration in this population carries higher risk.
▸ Subjective experience (deep)
Honest disclosure: subjective-effect reports for P21 are sparse compared to mainstream peptides. What's available from community logs:
- Days 1–7: Often nothing perceptible. Some users report mild relaxation, possible mild mood lift. Injection-site reactions occasional (mild burning, transient erythema) but generally well-tolerated.
- Days 7–21: Subjective verbal fluency, faster word retrieval, "things click together more easily" — but variable. Closer to the Cerebrolysin profile than to Semax (which has a more acute, energizing onset).
- Days 21–42 (4–6 week cycle): Cumulative effect peaks. Some users report improved sleep architecture and better recall on longer-term memory tasks.
- Post-cycle: Limited reports. The mechanism (neurogenesis + synaptic protein upregulation) implies that benefits should persist for weeks-to-months post-cycle — but no human data confirms this.
Comparison to Cerebrolysin subjective profile: Both are "subtle, infrastructural, not stim-like." Both designed for damaged brains; healthy-adult signal is contrastive (you notice the absence of fog, not the presence of stimulation). Cerebrolysin has a clearer community signal because it has 75+ years of clinical use and a much larger user base. P21 is at the "early adopter" stage where subjective data is noisy.
Injection experience (SC route most common): Small volume (100–300 mcg in 0.1–0.3 mL reconstituted solution). 27g–30g insulin needle, abdominal SC. Generally painless. Some users report mild warmth at injection site lasting <30 minutes.
Intranasal route: Anecdotally faster onset (minutes vs hours for SC), potentially lower effective dose due to direct CNS delivery via olfactory/trigeminal pathways. The adamantyl modification favors mucosal absorption. However, intranasal P21 protocols are even less standardized than SC, and home reconstitution into a nasal spray introduces sterility / dose-accuracy concerns.
▸ Tolerance + cycling deep dive
- Tolerance buildup: Unknown formally. Mechanism (neurogenesis + receptor-cascade activation) doesn't suggest classical receptor downregulation, but the field consensus across all neurotrophic peptides (Cerebrolysin, Semax, NASA, P21) is to cycle pulsed-on / off rather than chronic continuous.
- Recommended cycle: 4–8 weeks on, 4–8 weeks off. Mirrors the rodent protocol durations.
- Reset protocol: No formal reset needed. If discontinuing entirely, no taper required — peptide clears in hours, downstream neurogenesis effects fade over weeks.
▸ Stacking deep dive
Synergistic with
- adamax — Both incorporate adamantyl modification; complementary cognitive benefits through different neuropeptide pathways. Per pep-pedia interaction matrix, P21 + Adamax flagged "Synergistic." Unclear whether this is mechanistic claim or vendor marketing — caveat.
- semax / n-acetyl-semax-amidate (NASA) — Compatible per pep-pedia. Different mechanisms (CNTF vs melanocortin) → complementary cognitive benefits. NASA daily intranasal + P21 cyclic SC could be a "chronic baseline + cyclic surge" structure analogous to NASA + Cerebrolysin. For the user: NASA already locked, no need to add P21.
- selank — Compatible. Complementary cognitive + anxiolytic effects through different receptor systems.
- bpc-157 — Compatible. Different mechanisms (neurogenesis vs tissue repair / gut-brain axis). Already in the user's V stack.
- cerebrolysin — Per pep-pedia: "P21 was developed as a defined alternative to Cerebrolysin. Both promote neurogenesis but P21 has defined structure and better BBB penetration." Stacking these together is not recommended for users in this archetype — they hit the same axis, you lose attribution, and P21 doesn't add evidence-supported benefit beyond what Cerebrolysin already delivers. Run them in separate cycles if at all.
- NAD+ / NMN — Compatible. Complementary mechanisms — NAD+ supports cellular energy metabolism while P21 promotes neurogenesis + synaptic plasticity.
- epitalon — Compatible. Different mechanisms (telomerase / pineal vs neurogenesis).
- omega-3 / DHA, citicoline, NAC, curcumin (all V4) — Synergistic anti-inflammatory + membrane substrate environment that any neurotrophic peptide operates better in.
Avoid stacking with
- dihexa — Per pep-pedia: "Use Caution. Both affect neuroplasticity strongly through different pathways (CNTF/BDNF vs HGF/c-Met) — avoid concurrent use without careful cycling." Theoretical excess plasticity / unpredictable interaction. Run one or the other, not both.
- Other strong neurotrophic peptides simultaneously (Cerebrolysin, dihexa, multiple BDNF-axis stimulators) — same logic. Pick one neurotrophic intervention per cycle, see what it does, then iterate.
- Lithium chronic — Both modulate GSK3β. Theoretical compound effect; not well-characterized.
Neutral / safe co-administration
- All V4 daily core supplements
- Modafinil (no documented interaction)
- Bromantane, ALCAR, taurine, apigenin
- Creatine, beta-alanine, electrolytes
- Most other V5 candidates (Selank, Adamax at separate windows)
▸ Drug interactions deep dive
- No documented clinical drug interactions — P21 has not been studied formally enough to characterize human DDIs.
- CYP enzymes: Peptide; no significant CYP induction or inhibition documented or expected. Should not affect modafinil (CYP3A4) or selegiline (CYP2B6/3A4) metabolism.
- MAOIs: No documented interaction. Mechanistically distinct from monoamine pathways.
- SSRIs / SNRIs: No documented interaction.
- Anticoagulants / antiplatelets: No documented interaction.
- Alcohol: No documented interaction. (the user alcohol-free, non-issue.)
- Caffeine, nicotine: No interaction.
- Hormonal contraceptives: No interaction (irrelevant for users in this archetype).
▸ Pharmacogenomics
- No specific pharmacogenomic profile for P21. Too early in development for human pharmacogenomic studies.
- Indirect relevance:
- BDNF Val66Met (rs6265) — Met carriers have reduced activity-dependent BDNF release. P21 drives BDNF upregulation, so theoretically Met carriers may benefit more from P21 (compensating for reduced endogenous secretion). Same logic as for Cerebrolysin and Semax. Speculative until human data exists.
- CNTF receptor SNPs — uncharacterized clinically. CNTFRα variants exist but are not in standard 23andMe / Ancestry panels.
- GSK3β-related SNPs — rare; not actionable currently.
- APOE ε4 — relevant to the AD use case (P21's primary research indication). Not actionable for users in this archetype at age 20.
Action item post-23andMe (June 2026): Pull BDNF Val66Met (informs all neurotrophic-peptide response prediction). No P21-specific genotype to check.
▸ Sourcing deep dive
| Path | Vendor | Cost (5 mg vial typical) | Reliability | Notes |
|---|---|---|---|---|
| Research-chem (gray market) | Real Peptides, Nationwide Peptides, Polar Peptides, Peptide Sciences | $50–$150/vial (5 mg lyophilized) | medium — variable | Marketed as "research only." Quality varies dramatically by vendor; demand COA with HPLC purity (>98%), mass spec confirmation, endotoxin (<0.5 EU/mg). Reconstitution + dosing fully on the user. |
| Clinical / Rx (US) | Not available | n/a | n/a | P21 is not FDA-approved and not available via compounding pharmacies as of 2026. Some telehealth peptide clinics may offer it as research-grade reconstituted peptide; verify product source and pay a markup. |
| Direct from developer | Phanes Biotech / PhaseRx (Maccecchini) | n/a — clinical trial only | n/a | If a Phase 2 trial opens (Alzheimer's or TBI indication), enrollment may be the only legitimate route. Currently no open trials a user in this archetype would qualify for. |
Cost math for users in this archetype (hypothetical 6-week SC cycle at 200 mcg ED):
- 6 weeks × 7 days × 200 mcg = 8.4 mg total → need ~2 × 5 mg vials per cycle
- Cost per cycle: ~$100–$300 at gray-market vendors
- If running 2–3 cycles per year: $200–$900/yr
- For the user's currently: skip — Cerebrolysin's $720/yr already covers the same mechanism with better evidence. Adding P21 is double-spending the same axis.
Sourcing risk: Higher than Cerebrolysin. Cerebrolysin is a finished pharmaceutical product manufactured by EVER Pharma to GMP standards in Austria; P21 from gray-market vendors is reconstituted from lyophilized synthesized peptide of unverified provenance. Without third-party HPLC + mass spec verification, you're dosing an unknown.
Quality verification on receipt:
- Lyophilized powder should be white, fluffy, no discoloration
- Vial sealed, intact rubber stopper
- COA with HPLC purity, mass spec (M+H confirming MW ~578.3 Da), endotoxin
- If COA absent or any flag → don't use
▸ Biomarkers to track (deep)
Baseline (before any cycle, if the user ever runs P21)
- Standard V4 bloodwork (June 2026 panel)
- Serum NfL, GFAP — neurotrophic-peptide outcome markers
- Cognitive battery (CNS Vital Signs / Cambridge Brain Sciences)
- BDNF Val66Met (post-23andMe)
- Sleep architecture (Oura/Whoop baseline)
During use
- Daily subjective effect log (sleep, cognition, mood, training recovery, injection-site reaction)
- Watch for any anomalous mood / cognitive changes
- Adverse event log
Post-cycle
- 2 weeks post-cycle: repeat cognitive battery
- 4 weeks post-cycle: repeat NfL / GFAP if budget permits
- Comparison to Cerebrolysin cycle data — does P21 deliver any signal Cerebrolysin doesn't?
▸ Controversies / open debates Live debate
- Generalizability of rodent data to humans. The strongest P21 evidence is in 3xTg-AD mice — a tau + Aβ + presenilin transgenic model that recapitulates human AD pathology better than most, but is still a mouse. The historical track record of AD drug development is grim: dozens of compounds with strong preclinical data have failed in human Phase 3. P21's defined structure + clean preclinical safety + oral bioavailability are favorable, but human translation is not guaranteed.
- Mechanism-redundancy with Cerebrolysin. Both compounds target the neurotrophic / BDNF axis. The pep-pedia entry positions P21 as "a defined alternative to Cerebrolysin" — implying advantages of structural definition + better BBB penetration. Whether these advantages translate to greater clinical benefit in humans is untested. For practical use right now, Cerebrolysin's 75-year clinical track record dominates.
- Vendor / sourcing quality. Gray-market peptide quality is wildly variable. Without third-party HPLC + mass spec on every batch, users may be dosing degraded peptide, wrong sequence, or contaminated product. This is the single biggest practical risk for P21 use today.
- Adamantyl modification long-term safety. Adamantane is the same cage hydrocarbon found in amantadine (FDA-approved antiparkinsonian/antiviral). Long-term adamantyl-tagged peptide exposure has not been characterized in humans. Theoretical risk minimal, but worth flagging.
- Phanes Biotech / PhaseRx clinical development pace. Slow. The compound has been in "early clinical development" status for ~5+ years without a major Phase 2 readout. This may reflect funding constraints rather than efficacy concerns, but it leaves the human evidence gap unfilled.
- No subconcussive-impact RCT exists for P21 — same gap as Cerebrolysin, except P21 has even less acute-TBI human data to extrapolate from. The MMA brain-protection use case is mechanistically appealing but completely uncharted for P21 specifically.
▸ Verdict change log
- 2026-05-06 — Initial verdict: WATCH-LIST (LOW confidence). P21 is a mechanistically interesting CNTF-derived neurogenic peptide with robust preclinical (rodent AD/TBI/aging) data, but human evidence is essentially absent (Phase 1 safety only). For combat-sport context brain-protection thesis, Cerebrolysin already covers the neurotrophic-mimetic axis with A-tier human RCT support, decades of clinical use, and reliable gray-market sourcing — P21 would be mechanism-redundant double-spending without adding evidence-backed benefit. Sourcing is hard (gray-market only, variable QC). Verdict for users in this archetype: WATCH-LIST low. Re-evaluate if Phanes Biotech publishes a Phase 2, if a reliable QC'd vendor channel emerges, or if the user's first 2–3 Cerebrolysin cycles leave subjective gaps that suggest a complementary neurogenic intervention is warranted.
▸ Open questions / gaps Open
- No Phase 2 human efficacy data — the single biggest gap. Whether the rodent 3xTg-AD effects translate to humans is unknown. Phanes Biotech / PhaseRx development pace is slow; no near-term readout expected.
- Subconcussive-impact prophylaxis in athletes — completely uncharted for P21 specifically. Same mechanistic appeal as Cerebrolysin, but no data layer to support extrapolation.
- Optimal dose and cycle length for human use — community 100–300 mcg SC × 4–8 weeks is extrapolated from rodent allometry. No Phase 1 dose-finding data publicly available.
- Intranasal vs SC efficacy and PK in humans — preclinical data favors both routes due to adamantyl modification, but human comparative PK has not been published.
- Long-term safety beyond 18 months — rodent 18-month data is favorable, but lifetime exposure (if used for years as a chronic neuroprotective layer) carries unknown risks. GSK3β downstream effects, off-target proliferation theoretical concerns warrant longer studies.
- Vendor quality verification — third-party COA + HPLC + mass spec testing of multiple gray-market P21 vendors would be high-value for the community. No reliable independent test results published as of 2026.
- Comparative head-to-head with Cerebrolysin / Semax / NASA — does P21 deliver meaningfully more / different / better neurotrophic benefit than these established peptides? Without comparative human data, Cerebrolysin's evidence base wins by default.
- WADA classification trajectory — currently unclassified, but CNTF-mimetic peptides could fall under future "growth factor" or "peptide hormone analog" categorizations. Verify before any sanctioned competition.
References
P21 Discovery Study (Li et al. 2010, FEBS Letters)
original P21 (Ac-DGGLAG-NH2) demonstrating enhanced learning + memory + neurogenesis in normal C57BL/6 mice
View StudyP021 in 3xTg-AD long-term efficacy (Kazim et al. 2014, Neurobiology of Disease)
chronic oral P021 reduced tau hyperphosphorylation, increased BDNF, rescued cognition
View StudyP21 in TBI mouse model (Chohan et al. 2015, Neuroscience)
controlled cortical impact + Peptide 6 (P21 parent), 80% increase in DG newborn neurons, reversed dendritic + synaptic loss
View StudyP021 prevention of cognitive impairment (Baazaoui & Iqbal 2017, Neurobiology of Aging)
early-stage AD model, prevention of dendritic + synaptic deficits
View StudyComprehensive P021 review (Baazaoui & Iqbal 2022, Biomolecules)
AD therapeutic opportunity, 18-month chronic safety, oral bioavailability, >3h plasma half-life
View StudyP021 in CDKL5 deficiency (Fuchs et al. 2024, J Neurodev Disorders)
in vitro restoration of neuronal deficits, limited in vivo benefit; first published negative datapoint
View StudyCognitive Vitality Assessment of P021 (ADDF, 2025)
Alzheimer's Drug Discovery Foundation independent expert assessment of preclinical efficacy + clinical development status with Phanes Biotech
View Sourcepep-pedia P21 entry
composition, mechanism, interaction matrix, dosing protocols (community + research-derived)
View SourceCNTF biology + receptor pharmacology (review, Annu Rev Neurosci)
background on the CNTF/CNTFRα/gp130/LIFR receptor complex P21 mimics
View SourceAdamantane modification for BBB penetration (review)
chemistry of adamantyl-tagged peptides for CNS delivery
View SourceCerebrolysin compound file (sibling reference)
for comparison of evidence base + practical positioning
View SourcePPInteractions8 compounds▸
| Peptide | Status | Note |
|---|---|---|
Adamax | Synergistic | Adamax incorporates adamantyl portion from P21, may complement cognitive benefits through different neuropeptide pathways |
Semax | Compatible | Both are neuropeptides with established nootropic effects. Different mechanisms (CNTF vs melanocortin) may provide complementary cognitive benefits |
Selank | Compatible | Complementary cognitive and anxiolytic effects through different receptor systems |
Dihexa | Use Caution | Both affect neuroplasticity strongly through different pathways (CNTF/BDNF vs HGF/c-Met) - avoid concurrent use without careful cycling |
BPC-157 | Compatible | Different mechanisms - P21 targets neurogenesis/cognition, BPC-157 focuses on tissue repair and gut-brain axis |
Cerebrolysin | Similar | P21 was developed as a defined alternative to Cerebrolysin. Both promote neurogenesis but P21 has defined structure and better BBB penetration |
NAD+ | Compatible | Complementary mechanisms - NAD+ supports cellular energy metabolism while P21 promotes neurogenesis and synaptic plasticity |
Epitalon | Compatible | Different mechanisms - Epitalon targets telomerase/pineal function while P21 focuses on neurogenesis and cognitive enhancement |
PP Community insights — click to load ▸
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.